GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet®, the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants. The DNA-based vaccines will be delivered intramuscularly in the clinical trial exclusively using the PharmaJet Stratis® Needle-free Injection System.
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of DNA-based vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. By intelligent design, these vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. The two next-generation RBD and T-cell based vaccine candidates, developed in collaboration with Adaptive Biotechnologies, are designed to respond to existing and potentially future emerging COVID-19 variants with increased transmissibility and/or infectivity. While the initial focus for both candidates is as a booster vaccine for currently available vaccines, in the future they may consider additional primary and therapeutic applications. Both vaccines will be delivered exclusively needle-free.
“We are pleased that Nykode Therapeutics is moving into clinical trials with their DNA-based COVID-19 vaccines using our PharmaJet Needle-free Injection System,” commented Chris Cappello, President and CEO, PharmaJet. “As the fight continues against COVID-19, the integration of vaccine innovations with more efficacious delivery technologies, like needle-free jet injection, will be crucial for addressing the current and future pandemics.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
PharmaJet’s mission is to improve people’s lives through needle-free technology. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong, and long-lasting antigen specific immune responses and elicit efficacious clinical responses. The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron, within oncology and infectious diseases, and collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development. For more information visit https://www.nykode.com.